Filtered By:
Source: The American Journal of Cardiology
Condition: Atrial Fibrillation
This page shows you your search results in order of date. This is page number 10.
Order by Relevance | Date
Total 336 results found since Jan 2013.
Lifetime Pattern of Atrial Fibrillation and the Risks of Stroke and Death in a Population-based Cohort of Men (From The Manitoba Follow-Up Study)
Atrial Fibrillation (AF) is associated with stroke and mortality. The arrhythmia can be sustained or intermittent. Prior studies that have used fixed covariates and short time horizons to examine the relationship between the pattern of AF and the occurrence of events have produced conflicting results. The Manitoba Follow-Up Study includes 3983 originally healthy men who have been followed with routine examinations since 1948. AF status during each visit was classified into the following patterns: free of AF, newly-diagnosed; intermittent AF – in sinus; intermittent AF – in AF; sustained AF.
Source: The American Journal of Cardiology - August 20, 2018 Category: Cardiology Authors: William F. McIntyre, Philip D. St John, Mahmoud Torabi, Robert B. Tate Source Type: research
Embolic and Other Adverse Outcomes in Symptomatic Versus Asymptomatic Patients with Atrial Fibrillation (from the ORBIT-AF Registry)
We examined the incidence of major adverse outcomes in patients with asymptomatic versus symptomatic AF using ORBIT-AF (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation), a nationwide US registry of AF patients. We compared stroke/non-CNS embolism, MACNE (Major Adverse Cardiovascular and Neurologic Events), bleeding, and death in 9,319 asymptomatic (defined by European Heart Rhythm Association (EHRA) score =1 or “no symptoms”) versus symptomatic patients.
Source: The American Journal of Cardiology - August 20, 2018 Category: Cardiology Authors: Munveer Thind, DaJuanicia N. Holmes, Marwan Badri, Karen S. Pieper, Amitoj Singh, Rosalia G. Blanco, Benjamin A. Steinberg, Gregg C. Fonarow, Bernard J. Gersh, Kenneth W. Mahaffey, Eric D. Peterson, James A. Reiffel, Jonathan P. Piccini, Peter R. Kowey, O Tags: Full Length Article Source Type: research
Outcomes With Novel Oral Anticoagulants in Obese Patients who Underwent Electrical Cardioversion for Atrial Tachyarrhythmias
The efficacy of novel oral anticoagulants (NOACs) in severely obese patients is uncertain as volume of distribution is related to weight, and few such patients were enrolled in the pivotal trials. As the month after direct-current cardioversion (DCCV) for atrial fibrillation and atrial flutter is a high-risk period for stroke, we sought to evaluate the safety of performing DCCV in obese patients on NOAC. All patients who underwent DCCV after ≥3 weeks of NOAC or therapeutic warfarin treatment without a previous transesophageal echocardiogram over a 3-year period at a single center were included.
Source: The American Journal of Cardiology - July 4, 2018 Category: Cardiology Authors: Rachel M. Kaplan, Celso L. Diaz, Theresa Strzelczyk, Cindy You, Basil Saour, Michelle Fine, Amar Trivedi, Mark J. Shen, Prasongchai Sattayaprasert, Alexandru B. Chicos, Rishi Arora, Susan Kim, Albert Lin, Nishant Verma, Bradley P. Knight, Rod S. Passman Source Type: research
Outcomes with Novel Oral Anticoagulants in Obese Patients Undergoing Electrical Cardioversion for Atrial Tachyarrhythmias
The efficacy of novel oral anticoagulants (NOACs) in severely obese patients is uncertain as volume of distribution is related to weight and few such patients were enrolled in the pivotal trials. As the month following direct-current cardioversion (DCCV) for atrial fibrillation and atrial flutter (AF/AFL) is a high-risk period for stroke, we sought to evaluate the safety of performing DCCV in obese patients on NOAC. All patients who underwent DCCV after ≥ 3 weeks of NOAC or therapeutic warfarin treatment without a prior transesophageal echocardiogram (TEE) over a 3-year period at a single center were included.
Source: The American Journal of Cardiology - July 4, 2018 Category: Cardiology Authors: Rachel M. Kaplan, Celso L. Diaz, Theresa Strzelczyk, Cindy You, Basil Saour, Michelle Fine, Amar Trivedi, Mark J. Shen, Prasongchai Sattayaprasert, Alexandru B. Chicos, Rishi Arora, Susan Kim, Albert Lin, Nishant Verma, Bradley P. Knight, Rod S. Passman Source Type: research
Atrial fibrillation after percutaneous patent foramen ovale closure
We read with interest the recent article by Smer et al (1). In a meta-analysis of randomized trials, the authors reported the efficacy and safety of percutaneous patent foramen ovale (PFO) closure for prevention of recurrent stroke, in patients with an index cryptogenic stroke. Among 3440 patients included (five trials), the authors found that PFO closure decreases the risk of stroke compared with medical therapy (2.8% vs 5.8%; RR 0.48, CI 0.27-0.87, p=0.01) but increases risk of atrial fibrillation or flutter (AF) (4.2% vs 0.7%; RR 4.55, CI 2.16-9.6, p=0.0001).
Source: The American Journal of Cardiology - June 5, 2018 Category: Cardiology Authors: Mohammad K. Mojadidi, Akram Y. Elgendy, Islam Y. Elgendy, Ahmed N. Mahmoud, Bernhard Meier Source Type: research
Meta-Analysis Comparing Catheter-Guided Ablation Versus Conventional Medical Therapy for Patients With Atrial Fibrillation and Heart Failure With Reduced Ejection Fraction
The prognostic benefit of catheter ablation (CA) for atrial fibrillation in the setting of heart failure (HF) with reduced ejection fraction (EF) is unclear. A systematic search of medical literature was limited to randomized controlled trials. The primary outcome was all-cause mortality, and secondary outcomes were HF hospitalizations, stroke, left ventricular EF improvement, change in 6-minute walk test, and change in Minnesota living with HF questionnaire ( Δ MLHFQ). Random effects risk ratios (RR) were calculated for categorical outcomes and standardized mean differences (SMD) for continuous ones, using Der-Simonian and Liard model.
Source: The American Journal of Cardiology - June 4, 2018 Category: Cardiology Authors: Akram Y. Elgendy, Ahmed N. Mahmoud, Muhammad S. Khan, Maryam R. Sheikh, Mohammad K. Mojadidi, Mohamed Omer, Islam Y. Elgendy, Anthony A. Bavry, Kenneth A. Ellenbogen, William M. Miles, Matthew McKillop Source Type: research
Meta-analysis Comparing Catheter Guided Ablation Versus Conventional Medical Therapy for Patients with Atrial Fibrillation and Heart Failure with Reduced Ejection Fraction
The prognostic benefit of catheter ablation (CA) for atrial fibrillation (AF) in the setting of heart failure (HF) with reduced ejection fraction (EF) is unclear. A systematic search of medical literature was limited to randomized controlled trials. The primary outcome was all-cause mortality and secondary outcomes were HF hospitalizations, stroke, left ventricular EF improvement, change in 6-minute walk test ( Δ 6MWT) and change in Minnesota living with heart failure questionnaire (Δ MLHFQ). Random effects risk ratios (RR) were calculated for categorical outcomes and standardized mean differences (SMD) for continuous on...
Source: The American Journal of Cardiology - June 4, 2018 Category: Cardiology Authors: Akram Y. Elgendy, Ahmed N. Mahmoud, Muhammad S. Khan, Maryam R. Sheikh, Mohammad K. Mojadidi, Mohamed Omer, Islam Y. Elgendy, Anthony A. Bavry, Kenneth A. Ellenbogen, William M. Miles, Matthew McKillop Source Type: research
Relation of Electrocardiographic Left Atrial Abnormalities to Risk of Stroke in Patients with Atrial Fibrillation
The P wave terminal force in lead V1 (PTFV1) on the 12-lead ECG quantifies left atrial (LA) structural and electrophysiological abnormalities. We aimed to evaluate the association between PTFV1 and cerebrovascular accident (CVA) as well as LA structure and function in patients with atrial fibrillation (AF). We conducted a cross-sectional study of 229 patients with AF (60 ±10 years, 72% male) with (n=21) and without (n=208) a history of CVA, who underwent pre-ablation ECG and cardiac magnetic resonance (CMR) in sinus rhythm.
Source: The American Journal of Cardiology - May 2, 2018 Category: Cardiology Authors: Yuko Y. Inoue, Esra G. Ipek, Irfan M. Khurram, Luisa Ciuffo, Jonathan Chrispin, Stefan L. Zimmerman, Joseph E. Marine, John Rickard, David D. Spragg, Saman Nazarian, Kengo Kusano, Joao A. Lima, Ronald D. Berger, Hugh Calkins, Hiroshi Ashikaga Source Type: research
Influence of Sociodemographic Factors and Provider Specialty on Anticoagulation Prescription Fill Patterns and Outcomes in Atrial Fibrillation
We examined anticoagulant fills in 223,891 patients with incident non-valvular AF (mean age=71 years; 44% female; 84% white; 9% black; 5% Hispanic; 2% Asian) from the Optum Clinformatics database (2009-2014). Provider specialty and filled anticoagulant prescriptions 3 months prior to and 6 months after AF diagnosis were obtained.
Source: The American Journal of Cardiology - April 30, 2018 Category: Cardiology Authors: Wesley T. O'Neal, Pratik B. Sandesara, J'Neka S. Claxton, Richard F. MacLehose, Lin Y. Chen, Lindsay G.S. Bengtson, Alanna M. Chamberlain, Faye L. Norby, Pamela L. Lutsey, Alvaro Alonso Source Type: research
Risk of Cardioembolic Stroke in Cancer Patients with Atrial Fibrillation
In a recent article in the journal, Elbadawi et al1 find that the risk of cerebrovascular accidents (CVA) in cancer patients with atrial fibrillation (AF) was lower than in non-cancer patients with AF. At first glance this may appear surprising in light of the higher risk of stroke of cancer patients generally2,3, particularly those with aggressive subtypes and/or metastatic disease. However, recent studies in patients with AF and cancer4,5 show no increase in stroke risk, seemingly indicating that the risk of cardioembolic stroke specifically is not higher than in cancer-free pacients.
Source: The American Journal of Cardiology - April 18, 2018 Category: Cardiology Authors: Marc Sorigue, Edurne Sarrate, Mireia Franch-Sarto, Juan-Manuel Sancho, Elisa Orna Source Type: research
Risk of Cardioembolic Stroke in Patients With Cancer and Atrial Fibrillation
In a recent article in the journal, Elbadawi et al1 find that the risk of cerebrovascular accidents (CVA) in patients with cancer and atrial fibrillation (AF) was lower than in patients with AF without cancer. At first glance, this may appear surprising in light of the higher stroke risk of patients with cancer in general,2,3 particularly those with aggressive subtypes and/or metastatic disease. However, recent studies in patients with AF and cancer4,5 show no increase in stroke risk, seemingly indicating that the risk of cardioembolic stroke specifically is not higher than in patients without cancer.
Source: The American Journal of Cardiology - April 18, 2018 Category: Cardiology Authors: Marc Sorigue, Edurne Sarrate, Mireia Franch-Sarto, Juan-Manuel Sancho, Elisa Orna Source Type: research
Risk of Cardioembolic Stroke in Cancer Patients with Atrial Fibrillation
In a recent article in the journal, Elbadawi et al1 find that the risk of cerebrovascular accidents (CVA) in cancer patients with atrial fibrillation (AF) was lower than in non-cancer patients with AF. At first glance this may appear surprising in light of the higher risk of stroke of cancer patients generally2,3, particularly those with aggressive subtypes and/or metastatic disease. However, recent studies in patients with AF and cancer4,5 show no increase in stroke risk, seemingly indicating that the risk of cardioembolic stroke specifically is not higher than in cancer-free pacients.
Source: The American Journal of Cardiology - April 18, 2018 Category: Cardiology Authors: Marc Sorigue, Edurne Sarrate, Mireia Franch-Sarto, Juan-Manuel Sancho, Elisa Orna Source Type: research
Effectiveness and Safety of Direct Oral Anticoagulants and Warfarin, Stratified by Stroke Risk in Patients With Atrial Fibrillation
The objective of the study was to examine how the comparative effectiveness and safety of direct oral anticoagulants (DOACs) and warfarin differ across subgroups of patients with atrial fibrillation defined by stroke risk (CHA2DS2-VASc score ≤3, 4 to 5, ≥6). Using Medicare claims data, we identified patients newly diagnosed with atrial fibrillation in 2013 to 2014 who initiated warfarin (n=12,354), apixaban (n=2,358), dabigatran (n=1,415), or rivaroxaban (n=5,139), and categorized them according to their CHA2DS2-VASc score (≤3, 4 to 5, ≥6).
Source: The American Journal of Cardiology - March 28, 2018 Category: Cardiology Authors: Inmaculada Hernandez, Yuting Zhang, Samir Saba Source Type: research
Effectiveness and Safety of Direct Oral Anticoagulants and Warfarin, Stratified by Stroke Risk in Patients with Atrial Fibrillation
The objective of the study was to examine how the comparative effectiveness and safety of direct oral anticoagulants (DOACs) and warfarin differ across subgroups of atrial fibrillation (AF) patients defined by stroke risk (CHA2DS2-VASc score ≤3, 4-5, ≥6). Using claims data from a 5% random sample of Medicare beneficiaries, we identified patients newly diagnosed with AF in 2013-2014 who initiated warfarin (n=12,354), apixaban (n=2,358), dabigatran (n=1,415) or rivaroxaban (n=5,139), and categorized them according to their CHA2DS2-VAS c score (≤3, 4-5, ≥6).
Source: The American Journal of Cardiology - March 28, 2018 Category: Cardiology Authors: Inmaculada Hernandez, Yuting Zhang, Samir Saba Source Type: research
Financial Implications and Impact of Pre-Existing Atrial Fibrillation on in-Hospital Outcomes in Patients Undergoing Transcatheter Aortic Valve Implantation (From the National Inpatient Database)
The objective of this study was to evaluate the financial implications and the impact of pre-existing atrial fibrillation (AF) on in-hospital outcomes in patients undergoing transcatheter aortic valve implantation (TAVI) using the Nationwide Inpatient Sample (NIS) database. We identified patients who underwent TAVI from 2011 to 2014. The primary endpoint was the effect of pre-existing AF on in-hospital mortality. Secondary endpoints included peri-procedural cardiac complications, stroke and hemorrhage requiring transfusion.
Source: The American Journal of Cardiology - March 14, 2018 Category: Cardiology Authors: Hossam Abubakar, Ahmed Salah Yassin, Emmanuel Akintoye, Khalid Bakhit, Mohit Pahuja, Mohamed Shokr, Randy Lieberman, Luis Afonso Source Type: research
